Dianthus Therapeutics Inc. (DNTH NASDAQ) stock market data APIs
$50.4552
-2.6(-5.2%)
as of February 6, 2026
Try our APIs with
free plan!
Dianthus Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Prev. Close
50.4552
Open
47.8569
High
51.8924
Low
47.4509
52 wk Range
13.365-57.5
Market Cap
2 013 M
Shares Outstanding
43 223 K
Revenue
3 078 K
EPS
-0.97
Beta
1.23
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Dianthus Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dianthus Therapeutics Inc. data using free add-ons & libraries
Get Dianthus Therapeutics Inc. Fundamental Data
Dianthus Therapeutics Inc. Fundamental data includes:
- Net Revenue: 3 078 K
- EBITDA: -140 198 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.55
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dianthus Therapeutics Inc. News
New
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last?
Dianthus Therapeutics, Inc. (DNTH) shares ended the last trading session 9.9% higher at $52.76. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight
DelveInsight Business Research LLP The generalized myasthenia gravis market in 7MM is expected to show positive growth during the forecast period (2025–2034), mainly driven by the anticipated launc...
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run
Key Points 20,000 shares were sold in a derivative transaction on Dec. 4, 2025, generating proceeds of $903,600 at a weighted average price of $45.18 per share. This transaction represented 100% of C...
Dianthus Therapeutics Enters Oversold Territory (DNTH)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a te...
Get Dianthus Therapeutics Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
